Herui Yao

14.4k citations

175 papers · 10.0k indexed · 6 hit papers · h-index 46

Impact in

Cancer Research top 0.1%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
Oncology top 0.5%
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers

Papers in

Cancer Research 63
- Cancer-related molecular mechanisms research 26
- Breast Cancer Treatment Studies 19
Oncology 96
- HER2/EGFR in Cancer Research 25
- Cancer Treatment and Pharmacology 21
- Cancer Immunotherapy and Biomarkers 20
- Cancer Cells and Metastasis 14

Co-authors: Erwei Song Qiang Liu Chang Gong Fengyan Yu Fengxi Su Shicheng Su Yandan Yao Judy Lieberman
Journals: Journal of Clinical Oncology (16 papers)Annals of Oncology (9 papers)Nature Communications (7 papers)Cancer Research (6 papers)Frontiers in Oncology (6 papers)
Partner nations: China United States Macao

In The Last Decade

Herui Yao

167 papers receiving 9.9k citations

Hit Papers

6 papers align trajectories log scale

CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness 2018 · 921 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Cell
2018 Nature Immunology
2015 Cancer Cell
2014 Cancer Cell
2011 Cancer Cell
2007 Cell

Peers

Countries citing papers authored by Herui Yao

Since Specialization

Citations

This map shows the geographic impact of Herui Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herui Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herui Yao more than expected).

Fields of papers citing papers by Herui Yao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herui Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herui Yao. The network helps show where Herui Yao may publish in the future.

Co-authors

The 25 scholars most cited alongside Herui Yao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Herui Yao Line = papers co-authored together Herui Yao links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Neoadjuvant Strategies for Triple Negative Breast Cancer: Current Evidence and Future Perspectives SHILAP Revista de lepidopterología ·Zhenjun Huang, Qing Peng, Luhui Mao, Wenhao Ouyang, Junya Nitta, E. Hjelseth, Haizhu Chen, I. Djati, Li Tang, Hu Y, Ying Wang, Wei Zhang, Herui Yao, Yunfang Yu	2025	4
2	LBA19 SHR-A1811 versus pyrotinib plus capecitabine in human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (BC): A multicenter, open-label, randomized, phase III study (HORIZON-Breast01) Annals of Oncology ·Erqun Song, Herui Yao, Yi Yang, Yuzhen Yin, Qiang Zhang, Song Wang, Quchang Ouyang, Tao Sun, Xian Wang, Wen Xie, B. Wang, Wei Li, Min Yan, Chang‐An Geng, Yue Peng, Yue Yang, Feng Dong, Yue Zhang, Lin Cheng, Xiaodong Zhu	2025	2
3	Unraveling the role of M1 macrophage and CXCL9 in predicting immune checkpoint inhibitor efficacy through multicohort analysis and single‐cell RNA sequencing SHILAP Revista de lepidopterología ·Yunfang Yu, Haizhu Chen, Wenhao Ouyang, Jin Zeng, Feliceto Jr. V. Lariba, Luhui Mao, Xueyuan Jia, Paola Filippi, Zehua Wang, Frà Paolo Crivelli, Zhenjun Huang, 光男青野, Herui Yao, Kang Zhang	2024	10
4	Deciphering the role of apoptosis signature on the immune dynamics and therapeutic prognosis in breast cancer: Implication for immunotherapy Frontiers in Genetics ·Yunfang Yu, Xueyuan Jia, Ksenia Vyacheslavovna Khramova, Q. Chen, Heran Deng, みどり井戸川, Xinxin Xie, Zehua Wang, Frà Paolo Crivelli, Wenhao Ouyang, Herui Yao, Jiannan Wu	2024	0
5	Expression of Concern: Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5 Clinical Cancer Research ·Stefano Cunietti, Fengyan Yu, Yangwei Liu, Juan Feng, Wei Tang, Herui Yao, L Pierini, Jianing Chen, Fengxi Su, Yan Zhang, Erwei Song	2024	1
6	Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer. Journal of Clinical Oncology ·Fei Ma, Mengyao Niu, Jingfen Wang, Herui Yao, Xian Wang, Erika Hamilton, Yehui Shi, Xinjun Liang, Nong Xu, Feng Lin, NRC Equipment Corp., Yuhong Zhou, Ziping Wei, Pamela N. Münster	2024	2
7	3MO Multimodal data fusion for improved risk stratification of breast cancer with multi-task 3D deep learning model: A multicenter study Annals of Oncology ·Jean‐Pierre Lehmann, Chu Bao-jun, Wenhao Ouyang, Frederik Godt Hansen, Qin Yao, Yongtao Tan, Roberts Dimiņš, Tao Li, Zhe Zhang, Jinfeng Wang, Herui Yao	2023	0
8	A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments International Journal of Cancer ·Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wěi Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Hadar Shema, Xiuyu Julie Cong, Mohammad Reza Behvarz	2023	27
9	Abstract P5-02-35: Radiomic biomarkers to predict the efficacy of anti-PD-1 immunotherapy-based combinational treatment in advanced breast cancer: a multi-center study Cancer Research ·Jieqiong Liu, Jianli Zhao, Zhixian Sun, Yunfang Yu, Zhongyu Yuan, Herui Yao, Ying Wang	2023	1
10	Abstract OT3-25-02: Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer, a single arm, multicenter phase II clinical trial Cancer Research ·Jianli Zhao, Liqun Guo, Rhousuke Sakai, EVERTON DAS NEVES GONÇALVES, Natalia Klinger, Herui Yao, Ying Wang	2023	1
11	Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer Nature Communications ·Jieqiong Liu, Ying Wang, Zhenluan Tian, Ying Lin, Hengyu Li, Zhaowen Zhu, Qiang Liu, Shicheng Su, Xiaoting Hua, Weijuan Jia, Yaping Yang, Kailash Makhijani, Herui Yao, Wen Jiang, Erwei Song	2022	67
12	Targeting regulator of G protein signaling 1 in tumor-specific T cells enhances their trafficking to breast cancer Nature Immunology ·Di Huang, Xueman Chen, Xin Zeng, Liyan Lao, Jiaqian Li, Yue Xing, Yiwen Lu, Qian Ouyang, Jianing Chen, Linbin Yang, Fengxi Su, Herui Yao, Qiang Liu, Shicheng Su, Erwei Song	2021	71
13	Use of personal protective equipment against coronavirus disease 2019 by healthcare professionals in Wuhan, China: cross sectional study BMJ ·Min Liu, Shouzhen Cheng, Alla I. Kulova, Yang Yang, Qingtang Zhu, Hui Zhang, Daya Yang, Shuyuan Cheng, Han Xiao, Jiwen Wang, Herui Yao, A. N. Ivanov, Yuqi Zhou, Sui Peng, Ming Kuang, Sunima Maskey, Kar Keung Cheng, Haipeng Xiao	2020	181
14	Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy Clinical Cancer Research ·Yan Nie, Hongyan Huang, Mingyan Guo, Jiewen Chen, Wei Wu, Wende Li, Xiaoding Xu, Xiaorong Lin, Wenkui Fu, Yandan Yao, Fang Zheng, Man‐Li Luo, Phei Er Saw, Herui Yao, Erwei Song, Hai Hu	2019	128
15	Stimuli-Responsive Polymer–Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy Nano Letters ·Phei Er Saw, Herui Yao, Chunhao Lin, Wei Tao, Omid C. Farokhzad, Xiaoding Xu	2019	115
16	Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation Cancer Research ·Yan Nie, Jianing Chen, Di Huang, Yandan Yao, Jiewen Chen, Lin Ding, Jiayi Zeng, Shicheng Su, Xue Chao, Fengxi Su, Herui Yao, Hai Hu, Erwei Song	2017	43
17	The novel long intergenic noncoding RNA UCC promotes colorectal cancer progression by sponging miR-143 Cell Death and Disease ·Fengting Huang, Wen‐Ying Chen, Ebru Serinsöz-Linke, Yanyan Zhuang, J.A.M. Baar, Md Sadeque Hossein Mithu, Juanfei Peng, Zhe Zhu, E. R. Caley, Yuanhua Li, Herui Yao, Shineng Zhang	2017	54
18	miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. PubMed ·Xing Yang, Qian Hu, Samuel Mateer, Xiaorong Lin, Jieqiong Liu, Xiao Lin, Xiao-Xiao Dinglin, Jiayi Zeng, Hai Hu, Man‐Li Luo, Herui Yao	2017	55
19	miR-21 Induces Myofibroblast Differentiation and Promotes the Malignant Progression of Breast Phyllodes Tumors Cancer Research ·Chang Gong, Yan Nie, Shaohua Qu, Himani Mali, Xiuying Cui, Herui Yao, Yunjie Zeng, Fengxi Su, Erwei Song, Qiang Liu	2014	75
20	Highs without lows The New Scientist ·Josef Casimir Hofmann, Fengxi Su, Herui Yao, Jisheng Chen	2006	3

About Herui Yao

Herui Yao is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 175 papers that have together received 10.0k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (26 papers), Advanced Breast Cancer Therapies (25 papers), HER2/EGFR in Cancer Research (25 papers), Cancer Treatment and Pharmacology (21 papers), Cancer Immunotherapy and Biomarkers (20 papers), RNA modifications and cancer (19 papers), Breast Cancer Treatment Studies (19 papers) and Cancer Cells and Metastasis (14 papers). The work is most often cited by research in Cancer Research (4.7k citations), Oncology (3.8k citations), Immunology (1.9k citations), Molecular Biology (5.9k citations) and Pulmonary and Respiratory Medicine (1.2k citations). Herui Yao has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Erwei Song, Qiang Liu, Chang Gong, Fengyan Yu, Fengxi Su, Fengxi Su, Shicheng Su, Yandan Yao, Judy Lieberman and Di Huang. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Nature Communications, Cancer Research and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact